Skip to main content

Meet with our product experts in one-on-one virtual sessions

Set Up a Meeting
Quick Connect

White Paper

Tech Sheet - Cabozantinib (S)-malate API

Tech Sheet - Cabozantinib (S)-malate API

Cabozantinib S-malate is an orally bioavailable, small molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity.

Dr. Reddy's API Offering*

  • We offer Cabozantinib S-malate – Crystalline form N2 (Innovator form).
  • Cabozantinib HCl is an alternate salt providing 505(b)(2) opportunities in the US and early launch opportunities in Europe, Brazil, Turkey, Mexico, and South Korea.
  • Dr. Reddy’s proposed synthetic process is IP-compliant.
  • We employ a quality-by-design (QbD) approach for efficient processes and high-quality output.
  • Effective control strategy for avoiding potential genotoxic and carcinogenic impurities
  • Assured process safety and scalability.
  • A short lead time of 120-180 days from the purchase order date (PO).

To learn more about our API offerings, please read the Tech sheet on Cabozantinib API by filling out the contact form below.

Note: *Products under patent(s) are offered only for R&D purposes U/S 107A of the Patent Act and not for commercial sale.

Explore other Whitepapers:

Know More

Download Now

Please fill the Contact form below in order to view the white paper


No information in this catalog - including any reference to any product or service - constitutes an offer for sale, or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, the research quantities of such products may be offered for the purpose of regulatory submissions, wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the patent scenario for their respective markets and will be responsible for all patent related liabilities. Products protected under valid patents in India are not available for commercial use but would be available for Section 107A purposes.

Checked out our

API Linkedin
page yet?

Follow this page to explore how our offerings can accelerate your formulation success

Click here to visit